Navigation Links
Spherix Announces Termination of Arla License Agreement
Date:6/23/2009

ial to study the use of Naturlose as a treatment for Type 2 diabetes. Its Spherix Consulting subsidiary provides scientific and strategic support for suppliers, manufacturers, distributors and retailers of conventional foods, biotechnology-derived foods, medical foods, infant formulas, food ingredients, dietary supplements, food contact substances, pharmaceuticals, medical devices, consumer products, and industrial chemicals and pesticides. For more information, please visit www.spherix.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of Naturlose, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our continuing efforts to develop Naturlose may be unsuccessful, our common stock could be delisted from the NASDAQ Capital Market, and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our current report on Form 8-K filed on October 10, 2007. Readers are cautioned n
'/>"/>

SOURCE Spherix Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Spherix Announces Full-Scale Production of Pharmaceutical Tagatose
2. Spherix Regains Full NASDAQ Compliance
3. Spherix to Exhibit at the BIO 2009 International Convention
4. Spherix Recruiting New Independent Director to Regain NASDAQ Compliance
5. Spherix Incorporated Announces the Death of A. Paul Cox, Jr., Chairman of the Board
6. Spherix Announces 2008 Financial Results
7. Spherix Reports 3rd Quarter Earnings
8. Spherix Transfers Stock Listing to Nasdaq Capital Market
9. Spherix Receives Nasdaq Letter Extending Minimum Bid Price Compliance Period
10. Spherix Receives NASDAQ Bid Price Deficiency Letter
11. Spherix Reports 1st Quarter Earnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Pittsburgh, PA (PRWEB) January 15, 2014 The ... Company, publisher of Food Safety Tech , an e-Journal ... has signed an agreement for the second year for the ... with Pittcon 2014. The partnership provides that the registration fee ...
(Date:1/15/2014)... Westlake Village, Calif. (PRWEB) January 15, 2014 ... cancer treatment and management through the genomic analysis of ... will offer Therapy Finder™, a web-based cancer decision support ... a reporting option with Cynvenio’s ClearID™ genomic test, Therapy ...
(Date:1/15/2014)... Canada (PRWEB) January 15, 2014 This ... on nonclinical and clinical safety assessment in biosimilars. , ... path for biosimilar drug development, however the complex nature ... to quality, safety and efficacy extremely challenging. Based on ...
(Date:1/15/2014)... Reston, VA (PRWEB) January 15, 2014 ... education have continued their sponsorship of an annual competition ... interest in, and access to, innovative STEM study. The ... , TEAMS: Tests of Engineering Aptitude, Mathematics, and ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5
... Blue Steel-Al Manhal Consortium, he stated that the agreement made would ... countries, cities, and governmental entities to solve the environmental ... ... (PRWEB) July 30, 2008 -- Spectrum Blue Steel Corporation announced today ...
... designed to accelerate recovery from central nervous system disorders, announced ... rehabilitative healthcare services, will expand the availability of the NESS ... System to 88 rehabilitation hospitals nationwide. , ... ...
... Development Of Lead Drug Candidates, MARKHAM, ON, ... of a CDN $45 million Series C financing. ... Tanabe Pharma Corporation ("MTPC"), and supported,by a number ... Inc., Caisse de Depot et Placement du Quebec, ...
Cached Biology Technology:Geecf: Spectrum Blue Steel Announces Strategic Partnership with Al Manhal International Group of Abu Dhabi to Deploy Biosphere Facilities 2 Bioness Announces NESS H200 and L300 Systems to Be Available at 88 HealthSouth Hospitals Nationwide 2 Bioness Announces NESS H200 and L300 Systems to Be Available at 88 HealthSouth Hospitals Nationwide 3Cytochroma Closes $45 Million Series C Financing 2Cytochroma Closes $45 Million Series C Financing 3
(Date:4/23/2014)... away from using triclosan as an antimicrobial ingredient in ... now scientists are reporting new evidence that appears to ... journal Chemical Research in Toxicology , found that ... promoted the growth of human breast cancer cells in ... Kyung-Chul Choi and colleagues note that hormonal imbalances seem ...
(Date:4/23/2014)... EMBO today announced Sophie Martin of the University ... EMBO Gold Medal. The award acknowledges her work to ... development of the cell. , Martin has been working ... in particular the way in which the spatial organization ... In the last 11 years, she has been using ...
(Date:4/23/2014)... disease is the first cause of dementia and affects ... cure has yet been found. One of the reasons ... cellular mechanisms which cause alterations in nerve transmissions and ... the disease., Researchers from the Institute of Neuroscience at ... mechanism involved in memory consolidation and were able to ...
Breaking Biology News(10 mins):In lab tests, the antimicrobial ingredient triclosan spurs growth of breast cancer cells 2EMBO Gold Medal 2014 awarded to Sophie Martin 2Loss of memory in Alzheimer's mice models reversed through gene therapy 2
... Jerusalem, January 11, 2010 Why do some people ... the other hand, taking the opposite tack by buying insurance ... from the Hebrew University of Jerusalem and two Asian universities ... The team set out to tackle the long-standing question ...
... an enzyme in the brain with a specific kind of ... stroke, new research suggests. In a study using mouse ... E, an alternative to the popular drugstore supplement, stopped the ... The Ohio State University researchers have been studying how this ...
... unknown species of spider has been discovered in the dune ... by a team of scientists from the Department of Biology ... endangered. "The discovery of this new spider illustrates our obligation ... team of scientists. The Sands of Samar are the ...
Cached Biology News:Why do people 'play the longshot' and buy insurance? It's in our genes 2Study reveals how one form of natural vitamin E protects brain after stroke 2Study reveals how one form of natural vitamin E protects brain after stroke 3New spider species discovered by University of Haifa scientists 2
Sigmas E-TOXATE (Limulus Amebocyte Lysate) test kits are intended for the detection and semiquantitation of endotoxins for research purposes. sensitivity 0.05-0.1 EU/mL...
... The Label IT siRNA Tracker Intracellular Localization ... directly label and deliver siRNA, of your ... for in vitro tracking experiments. Subcellular localization ... can be monitored following introduction of the ...
... MW: 60kDa (A) and 36kDa (C) ... pH 7.5, 500mM NaCl, 60mM 2-mercaptoethanol, ... 1mM DTT, and 0.1mg/ml serum albumin ... of proteins. Purification: DEAE chromatography, aminohexyl-agarose ...
... The Label IT siRNA Tracker Intracellular ... to directly label and deliver siRNA, of ... manner, for in vitro tracking experiments. Subcellular ... expression can be monitored following introduction of ...
Biology Products: